FeesSafety
Pluang+

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Analyst Insights
07 Oct 2026, 21:04 WIB
Alex Lavoie
View Source
Bullish
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated biopharmaceutical models based on recent prescription trends ahead of the company's third-quarter earnings. Other independent forecasts also suggest bullish long-term prospects for Eli Lilly, highlighting confidence in its growth potential despite a premium valuation.

As of Oct 07, 2026 22:51 WIB, Eli Lilly (LLY) shares trade at USD 1,204.24 on Pluang, up 4.04% in the past day. The stock shows active trading with a volume of 2,131,200 and a market cap of $1.03 trillion. Notably, the dividend yield stands at 0.6%, reflecting modest income potential for shareholders.

More News (LLY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App